Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.


Type
Article
Change log
Authors
Ritchie, Craig W 
Russ, Tom C 
Banerjee, Sube 
Barber, Bob 
Boaden, Andrew 
Abstract

Since the publication of this article [1], it has come to the attention of the authors that information for one of the authors was not included in the competing interests section. Craig Richie has declared potential competing interests with the following companies; Janssen, Eisai, Pfizer, Eli Lilly, Roche Diagnostics, Boeringher Ingleheim, Novartis, AC Immune, Ixico, Aridhia, Amgen, Berry Consultants, Lundbeck, Sanofi, Quintiles (IQVIA) and Takeda. The full competing interests section for this article can be found below.

Description
Keywords
1109 Neurosciences
Journal Title
Alzheimers Res Ther
Conference Name
Journal ISSN
1758-9193
1758-9193
Volume Title
Publisher
Springer Science and Business Media LLC
Sponsorship
Medical Research Council (MR/L023784/2)
Medical Research Council (MR/L023784/1)